Allakos Inc. (ALLK)
| Market Cap | 4.21B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -219.77M |
| Shares Out | 54.31M |
| EPS (ttm) | -3.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 373,169 |
| Open | 76.85 |
| Previous Close | 76.31 |
| Day's Range | 75.62 - 78.25 |
| 52-Week Range | 70.37 - 157.98 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 143.10 (+84.4%) |
| Earnings Date | Nov 8, 2021 |
About ALLK
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headqu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 143.10, which is an increase of 84.41% from the latest price.
News
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of sub...
Do Options Traders Know Something About Allakos (ALLK) Stock We Don't?
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/...
– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and...
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College ...
REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...
3 Biotech Stocks With Huge Catalysts Incoming
These drugmakers have big events that should occur before the end of 2021.
Implied Volatility Surging for Allakos (ALLK) Stock Options
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...
3 Biotech Stocks That Could Double Soon
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 E...
-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --
Moving Average Crossover Alert: Allakos (ALLK)
Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is...
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodeniti...
Bear Of The Day: Allakos (ALLK)
Bear Of The Day: Allakos (ALLK)
7 of the Best Pharma Stocks to Buy Now
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-...
Allakos Appoints Baird Radford as Chief Financial Officer
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil...
Are Options Traders Betting on a Big Move in Allakos (ALLK) Stock?
Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.
Allakos Appoints Natalie Holles to its Board of Directors
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...
Allakos Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell r...
Allakos Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and web...
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic...
REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related dise...